Research & Literature

The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.

Ko JJ, Xie W, Kroeger N, et al.

The Lancet. Oncology 2015; (16(3)):293-300.

Partial nephrectomy for T1 renal cancer can achieve an equivalent oncological outcome to radical nephrectomy with better renal preservation: the way to go.

Lai TC, Ma WK, Yiu MK

Hong Kong medical journal = Xianggang yi xue za zhi 2016; (22(1)):39-45 doi:10.12809/hkmj144482.

Paraneoplastic syndromes are associated with adverse prognosis among patients with renal cell carcinoma undergoing nephrectomy.

Moreira DM, Gershman B, Lohse CM, et al.

World journal of urology 2016; (34(10)):1465-72 doi:10.1007/s00345-016-1793-7.

[WHO classification 2016 and first S3 guidelines on renal cell cancer: What is important for the practice?].

Moch H

Der Pathologe 2016; (37(2)):127-33 doi:10.1007/s00292-016-0144-1.

Coexistence of Essential Thrombocythemia, Iron-Refractory Iron Deficiency Anemia and Renal Cell Carcinoma.

Namdaroğlu S, Tekgündüz E, Altuntaş F

Hematology reports 2016; (8(1)):6235 doi:10.4081/hr.2016.6235.

Review of renal cell carcinoma and its common subtypes in radiology.

Low G, Huang G, Fu W, et al.

World journal of radiology 2016; (8(5)):484-500 doi:10.4329/wjr.v8.i5.484.

Surveillance following surgery for nonmetastatic renal cell carcinoma.

Richards KA, Abel EJ

Current opinion in urology 2016; (26(5)):432-8 doi:10.1097/MOU.0000000000000308.

Contemporary Treatment of Metastatic Renal Cell Carcinoma.

Stukalin I, Alimohamed N, Heng DY

Oncology reviews 2016; (10(1)):295 doi:10.4081/oncol.2016.295.

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models.

Cho H, Du X, Rizzi JP, et al.

Nature 2016; (539(7627)):107-111 doi:10.1038/nature19795.

Systemic Therapy for Metastatic Renal-Cell Carcinoma.

Choueiri TK, Motzer RJ

The New England journal of medicine 2017; (376(4)):354-366 doi:10.1056/NEJMra1601333.

Clinicopathologic and Molecular Pathology of Collecting Duct Carcinoma and Related Renal Cell Carcinomas.

Seo AN, Yoon G, Ro JY

Advances in anatomic pathology 2017; (24(2)):65-77 doi:10.1097/PAP.0000000000000138.

The impact of T1 renal tumor characteristics on baseline renal function in patients undergoing partial nephrectomy: A renal scan based objective assessment.

Porpiglia F, Autorino R, Fiori C, et al.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2017; (43(8)):1598-1602 doi:10.1016/j.ejso.2017.05.017.

Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Motzer RJ, Jonasch E, Agarwal N, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2017; (15(6)):804-834 doi:10.6004/jnccn.2017.0100.

Optimal Surveillance Strategies After Surgery for Renal Cell Carcinoma.

Tyson MD, Chang SS

Journal of the National Comprehensive Cancer Network : JNCCN 2017; (15(6)):835-840 doi:10.6004/jnccn.2017.0102.

Erythrocytosis caused by giant chromophobe renal cell carcinoma: a case report indicating a 9-year misdiagnosis of polycythemia vera.

Guo R, Liang Y, Yan L, et al.

Chinese journal of cancer 2017; (36(1)):72 doi:10.1186/s40880-017-0238-z.

Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.

Ohe C, Smith SC, Sirohi D, et al.

The American journal of surgical pathology 2018; (42(3)):279-292 doi:10.1097/PAS.0000000000001000.

Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery.

Leibovich BC, Lohse CM, Cheville JC, et al.

European urology 2018; (73(5)):772-780 doi:10.1016/j.eururo.2018.01.005.

Rare and changeable as a chameleon: paraneoplastic syndromes in renal cell carcinoma.

Hegemann M, Kroeger N, Stenzl A, Bedke J

World journal of urology 2018; (36(6)):849-854 doi:10.1007/s00345-018-2215-9.

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Motzer RJ, Tannir NM, McDermott DF, et al.

The New England journal of medicine 2018; (378(14)):1277-1290 doi:10.1056/NEJMoa1712126.

Management of the Incidental Kidney Mass in the Nephrology Clinic.

Hu SL, Weiss RH

Clinical journal of the American Society of Nephrology : CJASN 2018; (13(9)):1407-1409 doi:10.2215/CJN.00860118.

Renal cell carcinoma for the nephrologist.

Perazella MA, Dreicer R, Rosner MH

Kidney international 2018; (94(3)):471-483 doi:10.1016/j.kint.2018.01.023.

Renal Angiomyolipoma: The Good, the Bad, and the Ugly.

Vos N, Oyen R

Journal of the Belgian Society of Radiology 2018; (102(1)):41 doi:10.5334/jbsr.1536.

Metastatic Renal Cell Carcinoma Presenting as Prolonged Pyrexia and Stauffer's Syndrome: Can a Routine Ultrasound Scan Fail to Detect a Renal Cell Carcinoma?

Fonseka CL, Kariyawasam AGTA, Singhapura SDAL, et al.

Case reports in radiology 2018; (2018()):4215041 doi:10.1155/2018/4215041.

Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.

Bex A, Albiges L, Ljungberg B, et al.

European urology 2018; (74(6)):805-809 doi:10.1016/j.eururo.2018.08.008.

Epidemiology and Risk Factors for Kidney Cancer.

Scelo G, Larose TL

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018; JCO2018791905 doi:10.1200/JCO.2018.79.1905.

Renal cell carcinoma staging: pitfalls, challenges, and updates.

Williamson SR, Taneja K, Cheng L

Histopathology 2019; (74(1)):18-30 doi:10.1111/his.13743.

Grading of renal cell carcinoma.

Delahunt B, Eble JN, Egevad L, Samaratunga H

Histopathology 2019; (74(1)):4-17 doi:10.1111/his.13735.

Benefit of nephron sparing surgery translates into lower cancer specific mortality in patients with localized renal cell carcinoma.

Mistretta FA, Mazzone E, Knipper S, Karakiewicz PI

Annals of translational medicine 2018; (6(Suppl 2)):S104 doi:10.21037/atm.2018.11.37.

An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma.

Dudani S, Savard MF, Heng DYC

European urology focus 2020; (6(1)):34-36 doi:10.1016/j.euf.2019.04.004.

National Norwegian Practice Patterns for Surgical Treatment of Kidney Cancer Tumors ≤7cm: Adherence to Changes in Guidelines May Improve Overall Survival.

Hjelle KM, Johannesen TB, Bostad L, et al.

European urology oncology 2018; (1(3)):252-261 doi:10.1016/j.euo.2018.04.001.

Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?

Larcher A, Wallis CJD, Bex A, et al.

European urology oncology 2019; (2(4)):365-378 doi:10.1016/j.euo.2019.04.007.

Cytoreductive nephrectomy: future directions.

Margulis V, Hakimi AA

Current opinion in urology 2019; (29(5)):540-541 doi:10.1097/MOU.0000000000000662.

Palpable Abdominal Mass is a Renal Oncocytoma: Not All Large Renal Masses are Malignant.

Dey S, Noyes SL, Uddin G, Lane BR

Case reports in urology 2019; (2019()):6016870 doi:10.1155/2019/6016870.

Outcomes of laparoscopic radical nephrectomy for elderly patients with localized renal cell carcinoma.

Lv J, Song R, Cai H, Lu C

Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2019; (24(5)):2147-2154.

Percutaneous Microwave Ablation versus Laparoscopic Partial Nephrectomy for cT1a Renal Cell Carcinoma: A Propensity-matched Cohort Study of 1955 Patients.

Yu J, Zhang X, Liu H, et al.

Radiology 2020; (294(3)):698-706 doi:10.1148/radiol.2020190919.

[Follow-up of renal cell carcinoma based on stage and initial treatment].

Doehn C, Siebels M, Steiner T

Der Urologe. Ausg. A 2020; (59(2)):162-168 doi:10.1007/s00120-020-01126-8.

Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically.

Yang B, Xia H, Xu C, et al.

BMC urology 2020; (20(1)):14 doi:10.1186/s12894-020-0584-z.

New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies.

Grimm MO, Leucht K, Grünwald V, Foller S

Journal of clinical medicine 2020; (9(2)) doi:10.3390/jcm9020565.

Percutaneous microwave ablation of renal cell carcinoma: practice guidelines of the ultrasound committee of Chinese medical association, interventional oncology committee of Chinese research hospital association.

Yu J, Yu XL, Cheng ZG, et al.

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2020; (37(1)):827-835 doi:10.1080/02656736.2020.1779356.

Identifying risk factors for chronic kidney disease stage 3 in adults with acquired solitary kidney from unilateral nephrectomy: a retrospective cohort study.

Zhang WJ, Wang ZY, Zhou WX, et al.

BMC nephrology 2020; (21(1)):397 doi:10.1186/s12882-020-02059-2.

Renal cell carcinoma metastasis to the maxillary bone successfully treated with surgery after vascular embolization: a case report.

Nishii N, Shimamoto H, Ohsako T, et al.

Journal of medical case reports 2020; (14(1)):193 doi:10.1186/s13256-020-02522-6.

Predictors of Recurrence for T3a RCC: A Recurring Conundrum.

Leopold Z, Srivastava A, Singer EA

Diagnostics (Basel, Switzerland) 2020; (10(11)) doi:10.3390/diagnostics10110983.

Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data.

Ishihara H, Takagi T, Kondo T, et al.

Japanese journal of clinical oncology 2021; (51(5)):793-801 doi:10.1093/jjco/hyaa232.

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.

Bedke J, Albiges L, Capitanio U, et al.

European urology 2021; (79(3)):339-342 doi:10.1016/j.eururo.2020.12.005.

Emerging Therapies for Advanced Clear Cell Renal Cell Carcinoma.

Toth AT, Cho DC

Journal of kidney cancer and VHL 2020; (7(4)):17-26 doi:10.15586/jkcvhl.2020.156.

Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario.

Allman KD, Ryan JC, Clair A, Yenser-Wood S

Journal of the advanced practitioner in oncology 2019; (10(5)):483-493 doi:10.6004/jadpro.2019.10.5.6.

Do children with solitary or hypofunctioning kidney have the same prevalence for masked hypertension?

Yel S, Günay N, Pınarbaşı AS, et al.

Pediatric nephrology (Berlin, Germany) 2021; (36(7)):1833-1841 doi:10.1007/s00467-020-04896-7.

Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.

Laccetti AL, Garmezy B, Xiao L, et al.

Cancer medicine 2021; (10(7)):2341-2349 doi:10.1002/cam4.3812.

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Choueiri TK, Powles T, Burotto M, et al.

The New England journal of medicine 2021; (384(9)):829-841 doi:10.1056/NEJMoa2026982.

New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.

Trpkov K, Hes O, Williamson SR, et al.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2021; (34(7)):1392-1424 doi:10.1038/s41379-021-00779-w.

Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry.

Strauss A, Schmid M, Rink M, et al.

Future oncology (London, England) 2021; (17(18)):2325-2338 doi:10.2217/fon-2020-1020.

Orbit and sinonasal metastasis as presenting sign of renal cell carcinoma.

Barajas-Ochoa Z, Suero-Abreu GA, Barajas-Ochoa A

BMJ case reports 2021; (14(4)) doi:10.1136/bcr-2020-240588.

Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: a systematic review.

Rizzo A, Mollica V, Dall'Olio FG, et al.

Future oncology (London, England) 2021; (17(20)):2671-2681 doi:10.2217/fon-2021-0069.

Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis.

Rizzo A, Mollica V, Santoni M, et al.

Immunotherapy 2021; (13(9)):783-793 doi:10.2217/imt-2021-0005.

Role of F-18 FDG PET/CT in the follow-up of asymptomatic renal cell carcinoma patients for postoperative surveillance: based on conditional survival analysis.

Park S, Lee HY, Lee S

Journal of cancer research and clinical oncology 2022; (148(1)):215-224 doi:10.1007/s00432-021-03688-2.

Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma.

Silagy AW, Kotecha RR, Weng S, et al.

Cancer 2021; (127(21)):3946-3956 doi:10.1002/cncr.33790.

Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey.

Bui KT, Kiely BE, Dhillon HM, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(1)):511-519 doi:10.1007/s00520-021-06454-9.

Impact of Positive Surgical Margins After Partial Nephrectomy.

Carvalho JAM, Nunes P, Tavares-da-Silva E, et al.

European urology open science 2020; (21()):41-46 doi:10.1016/j.euros.2020.08.006.

Prognostic significance of hemoglobin-to-red cell distribution width ratio in patients with metastatic renal cancer.

Yılmaz H, Yılmaz A, Demirağ G

Future oncology (London, England) 2021; (17(29)):3853-3864 doi:10.2217/fon-2021-0040.

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

Choueiri TK, Tomczak P, Park SH, et al.

The New England journal of medicine 2021; (385(8)):683-694 doi:10.1056/NEJMoa2106391.

Renal cell carcinoma, part 3.

Pullen RL

Nursing 2021; (51(9)):30-38 doi:10.1097/01.NURSE.0000769804.33935.a1.

How to Deal with Renal Cell Carcinoma >7 cm: Radical Surgery.

Grimm MO, Leucht K

European urology open science 2021; (33()):81-82 doi:10.1016/j.euros.2021.09.001.

Risk Stratification and Treatment Algorithm of Metastatic Renal Cell Carcinoma.

Grimm MO, Leucht K, Foller S

Journal of clinical medicine 2021; (10(22)) doi:10.3390/jcm10225339.

Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials.

Rizzo A, Mollica V, Santoni M, et al.

Future oncology (London, England) 2022; (18(5)):625-634 doi:10.2217/fon-2021-0888.

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

Motzer RJ, Jonasch E, Agarwal N, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(1)):71-90 doi:10.6004/jnccn.2022.0001.

Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC).

Rysz J, Franczyk B, Ławiński J, Gluba-Brzózka A

International journal of molecular sciences 2021; (23(1)) doi:10.3390/ijms23010151.

Chronic Kidney Disease in Cancer Survivors.

Lee M, Wang Q, Wanchoo R, et al.

Advances in chronic kidney disease 2021; (28(5)):469-476.e1 doi:10.1053/j.ackd.2021.10.007.

Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma.

Chen YW, Rini BI

Current oncology reports 2022; (24(6)):695-702 doi:10.1007/s11912-022-01196-1.

A clinical investigation of recurrence and lost follow-up after renal cell carcinoma surgery: a single-center, long-term, large cohort, retrospective study.

Arai T, Sazuka T, Sato H, et al.

International journal of clinical oncology 2022; (27(9)):1467-1476 doi:10.1007/s10147-022-02204-x.

THE JEREMIAH METZGER LECTURE:VON HIPPEL-LINDAU DISEASE: INSIGHTS INTO OXYGEN SENSING, CANCER AND DRUGGING THE UNDRUGGABLE.

Kaelin WG

Transactions of the American Clinical and Climatological Association 2022; (132()):170-181.

Clear Cell Renal Cell Carcinoma, Diagnostic and Therapeutic Difficulties, Case Report and Literature Review.

Stolpa W, Stręk-Cholewińska A, Mizia-Malarz A

Medicina (Kaunas, Lithuania) 2022; (58(10)) doi:10.3390/medicina58101329.

Pembrolizumab-induced encephalitis in a patient with renal cell carcinoma post nephrectomy: A case report.

Sharma A, Chapagain A, Kharel S, et al.

SAGE open medical case reports 2023; (11()):2050313X221149827 doi:10.1177/2050313X221149827.

Sporadic unilateral papillary renal cell carcinoma masquerading pyelonephritis: A case report.

Guguloth MN, Manzoor J, Kuchana SK, et al.

Clinical case reports 2023; (11(2)):e6976 doi:10.1002/ccr3.6976.

Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

Derry-Vick HM, Heathcote LC, Glesby N, et al.

Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

Clinical Characteristics of Molecularly Defined Renal Cell Carcinomas.

Hu X, Tan C, Zhu G

Current issues in molecular biology 2023; (45(6)):4763-4777 doi:10.3390/cimb45060303.

Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma.

Kuusk T, Bex A

Hematology/oncology clinics of North America 2023; (37(5)):907-920 doi:10.1016/j.hoc.2023.05.020.

The genomic and transcriptomic landscape of advanced renal cell cancer for individualized treatment strategies.

de Joode K, van de Geer WS, van Leenders GJLH, et al.

Scientific reports 2023; (13(1)):10720 doi:10.1038/s41598-023-37764-z.

A case report: A rare case of icteric variant of Stauffer's syndrome.

Abiharan P, Balagobi B, Gobishangar S, et al.

International journal of surgery case reports 2023; (108()):108455 doi:10.1016/j.ijscr.2023.108455.

Collecting duct carcinoma with retroperitoneal mass as initial presentation: a rare case report.

Ye R, Liao Y, Xia T, et al.

BMC urology 2023; (23(1)):127 doi:10.1186/s12894-023-01295-6.

Incidence and clinical relevance of paraneoplastic syndromes in patients with renal cell carcinoma.

Moldovan T, Boynton D, Kuperus J, et al.

Urologic oncology 2023; (41(9)):392.e11-392.e17 doi:10.1016/j.urolonc.2023.06.015.

Scan-Associated Distress in People Affected by Cancer: A Qualitative Systematic Review.

Hussain M, Chau S, Turner M, Paterson C

Seminars in oncology nursing 2023; (39(5)):151502 doi:10.1016/j.soncn.2023.151502.

Renal functional outcomes after nephrectomy in patients with localized renal cell carcinoma and diabetes mellitus: a systematic review and meta-analysis.

Yang Y, Meng L, Hu X, Li X

International urology and nephrology 2024; (56(6)):1859-1868 doi:10.1007/s11255-023-03885-7.

Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

Hereditary Renal Cancer Syndromes.

Yanus GA, Kuligina ES, Imyanitov EN

Medical sciences (Basel, Switzerland) 2024; (12(1)) doi:10.3390/medsci12010012.

Nurse-led renal cell carcinoma clinic: a single center review.

Thia I, Tan A, Botha E, et al.

ANZ journal of surgery 2024; (94(6)):1071-1075 doi:10.1111/ans.18920.

Efficacy Assessment of Post-nephrectomy Adjuvant Therapies in Patients with Renal Cell Carcinoma.

Ding K, Yang Z, Zhang D, Sun L

Annals of surgical oncology 2024; (31(6)):3894-3905 doi:10.1245/s10434-024-15121-2.

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

Choueiri TK, Tomczak P, Park SH, et al.

The New England journal of medicine 2024; (390(15)):1359-1371 doi:10.1056/NEJMoa2312695.

Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma.

Liao C, Hu L, Zhang Q

Nature reviews. Urology 2024; (21(11)):662-675 doi:10.1038/s41585-024-00876-w.

Sarcomatoid and Rhabdoid Renal Cell Carcinoma: Clinical, Pathologic, and Molecular Genetic Features.

Adeniran AJ, Shuch B, Humphrey PA

The American journal of surgical pathology 2024; (48(7)):e65-e88 doi:10.1097/PAS.0000000000002233.

End-stage renal disease after renal cancer surgery: risk factors and overall survival.

Åkerlund J, Ljungberg B, Lundstam S, et al.

Scandinavian journal of urology 2024; (59()):109-116 doi:10.2340/sju.v59.40322.

Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis.

Britton CJ, Andrews JR, Wallis CJD, et al.

Urologic oncology 2023; (41(3)):125-136 doi:10.1016/j.urolonc.2022.09.021.

Perioperative systemic treatments in renal cell carcinoma.

Goswamy R, Kalemoglu E, Master V, Bilen MA

Frontiers in oncology 2024; (14()):1362172 doi:10.3389/fonc.2024.1362172.

Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 Study.

Wiley HE, Srinivasan R, Maranchie JK, et al.

Ophthalmology 2024; (131(11)):1324-1332 doi:10.1016/j.ophtha.2024.05.024.

Renal mass biopsy - a practical and clinicopathologically relevant approach to diagnosis.

Mansour H, Tran-Dang MA, Walkden M, et al.

Nature reviews. Urology 2025; (22(1)):8-25 doi:10.1038/s41585-024-00897-5.

Renal Cell Carcinoma: A Review.

Rose TL, Kim WY

JAMA 2024; (332(12)):1001-1010 doi:10.1001/jama.2024.12848.

Advances in Molecular Mechanisms of Kidney Disease: Integrating Renal Tumorigenesis of Hereditary Cancer Syndrome.

Cicchetti R, Basconi M, Litterio G, et al.

International journal of molecular sciences 2024; (25(16)) doi:10.3390/ijms25169060.

Dermatomyositis in a young patient: A rare paraneoplastic syndrome of renal cell carcinoma.

André M, Macedo A, Metrogos V, et al.

IJU case reports 2024; (7(5)):359-363 doi:10.1002/iju5.12754.

Multi-sequence MRI-based radiomics model to preoperatively predict the WHO/ISUP grade of clear Cell Renal Cell Carcinoma: a two-center study.

Chen R, Su Q, Li Y, et al.

BMC cancer 2024; (24(1)):1176 doi:10.1186/s12885-024-12930-2.

Choosing the optimal therapy for metastatic renal cell carcinoma: Insights from a real-world comparative study.

Hara T, Teishima J, Okamura Y, et al.

International journal of urology : official journal of the Japanese Urological Association 2025; (32(1)):29-38 doi:10.1111/iju.15590.

Incidence and Pattern of Recurrence after Surgical Resection in Organ-Confined Renal Cell Carcinoma.

Kim J, Ham WS, Park JS, Jang WS

Yonsei medical journal 2024; (65(11)):623-628 doi:10.3349/ymj.2023.0587.

Diabetes Remission After Radical Nephrectomy in a Geriatric Patient With Obesity and Type 2 Diabetes-34 Months' Follow-Up.

Tripathi P, Kadam N, Sharma B, et al.

JCEM case reports 2024; (2(12)):luae210 doi:10.1210/jcemcr/luae210.

A clinical audit of adverse post-nephrectomy outcomes in renal cell carcinoma patients at a tertiary hospital in Queensland, Australia.

de Souza JC, Vangaveti V, Biros E, Mallett AJ

Journal of nephrology 2025; (38(5)):1357-1368 doi:10.1007/s40620-024-02173-6.

Renal Outcomes With Renin-Angiotensin System Blockers After Unilateral Nephrectomy.

Lee S, Yoon S, Kim S, et al.

Kidney international reports 2025; (10(1)):184-196 doi:10.1016/j.ekir.2024.09.022.

Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma.

Bedke J, Ghanem YA, Albiges L, et al.

European urology 2025; (87(4)):491-496 doi:10.1016/j.eururo.2025.01.014.

Comparative efficacy and safety of ablative therapies in the management of primary localised renal cell carcinoma: a systematic review and meta-analysis.

Huang RS, Chow R, Benour A, et al.

The Lancet. Oncology 2025; (26(3)):387-398 doi:10.1016/S1470-2045(24)00731-9.

Renal tumors with different histological types occurring in the same kidney: A case report.

Akihiro M, Udo K, Ito M, et al.

Urology case reports 2025; (59()):102991 doi:10.1016/j.eucr.2025.102991.

Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients.

Catalano M, Venturi G, Salfi A, et al.

Immunotherapy 2025; (17(4)):247-256 doi:10.1080/1750743X.2025.2482510.

Temporal trends of the disease burden of renal cell carcinoma from 1992 to 2019 in the US: a population-based analysis.

Chen R, Tang T, Han J, et al.

Cancer causes & control : CCC 2025; (36(10)):1093-1105 doi:10.1007/s10552-025-02007-1.

Systemic Treatment of Locally Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma.

Vento J, Zhang T, Kapur P, et al.

Cancers 2025; (17(9)) doi:10.3390/cancers17091527.

Chromophobe Renal Cell Carcinoma With Sarcomatoid Differentiation: A Case Report and Review of the Literature.

Omari M, Bendimya M, Jebrouni F, et al.

Cureus 2025; (17(4)):e83143 doi:10.7759/cureus.83143.

A case of renal cell carcinoma with tumor thrombus extension into the right atrium.

Whiting A, Shah N, Zucker J, et al.

Annals of medicine and surgery (2012) 2025; (87(6)):3819-3822 doi:10.1097/MS9.0000000000002837.

Biological and Clinical Insight into the Prevention and Management of Metastatic Renal Cell Carcinoma with a Sarcomatoid Component.

Salgia NJ, Fujiwara Y, Xu B, et al.

European urology focus 2025; (11(3)):421-424 doi:10.1016/j.euf.2025.05.011.

Contemporary Outcomes of Robot-Assisted Partial Nephrectomy: Results from Two European Referral Institutions.

Barletta F, Frego N, de Angelis M, et al.

Cancers 2025; (17(13)) doi:10.3390/cancers17132104.

Management and optimization of chronic renal insufficiency in the setting of kidney cancer A Systematic Review.

Cobb JK, Miyagi H, Chahoud J, et al.

International braz j urol : official journal of the Brazilian Society of Urology 2025; (51(5)).

Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy.

Cushman CJ, Abaleka F, Ibrahim AF, et al.

Reports (MDPI) 2024; (7(4)) doi:10.3390/reports7040091.

Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

Shah MS, Memon JA, Malik U, et al.

Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

Hereditary syndromes and RCC: what radiologists need to know.

Charbel C, Withey SJ, Serrao E, et al.

Abdominal radiology (New York) 2026; (51(6)):3038-3053 doi:10.1007/s00261-025-05302-2.

Targeting of HIF2-driven cachexia in kidney cancer.

Abu-Remaileh M, Stransky LA, Bhalerao N, et al.

Nature medicine 2026; (32(1)):245-257 doi:10.1038/s41591-025-04054-2.

Radiologic, Pathologic, and Deep Learning Predictors of Response to Immune Checkpoint Blockade in Renal Cell Carcinoma Patients Undergoing Post-Treatment Nephrectomy.

Kapur P, Christie A, Jarmale V, et al.

medRxiv : the preprint server for health sciences 2025; doi:10.1101/2025.11.19.25340277.